Literature DB >> 22326038

The use of radiation therapy in the geriatric population.

Benjamin Rosenbluth1.   

Abstract

The foregoing, it is hoped, has provided at least a taste of the past, present, and future in the use of RT for the elderly population. Based on many ongoing studies, it becomes clear that the radiation oncology world has come to recognize the geriatric population’s ability to tolerate, and perhaps even thrive from, a course of RT, when it is offered appropriately. In the final analysis, it has become clear that no simple age cutoff can substitute for clinical acumen and a thorough assessment of patients’ general health before the best treatment regimen can be chosen. One need only follow the trend both in American and in European trials (the RTOG and the EORTC) to appreciate the acceptance that has taken hold that there need not be an age cutoff so much as a set of clinical criteria, including performance status and other assessments of function and comorbidity, prior to patient enrollment in anational trial. With such an outlook, we eagerly anticipate the results from these trials and look forward to implementing them in our treatment of young and old patients alike.

Entities:  

Mesh:

Year:  2012        PMID: 22326038     DOI: 10.1016/j.cger.2011.12.001

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  2 in total

1.  The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly.

Authors:  Marta Scorsetti; Elena Clerici; Piera Navarria; Giuseppe D'Agostino; Lorenzo Piergallini; Fiorenza De Rose; Annamaria Ascolese; Angelo Tozzi; Cristina Iftode; Elisa Villa; Tiziana Comito; Ciro Franzese; Pietro Mancosu; Stefano Tomatis; Luca Cozzi
Journal:  Br J Radiol       Date:  2015-07-17       Impact factor: 3.039

Review 2.  Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients.

Authors:  Ignacio Morales-Orue; Juan Zafra-Martin; Laura Garcia; Rodolfo Chicas-Sett; Juan Castilla-Martinez; Maria Auxiliadora Cabezon; Javier Burgos; Marta Lloret; Pedro C Lara
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.